Stock 002603 SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Share Price

Equities

002603

CNE1000015S0

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 25/04/2024 BST 		5-day change 1st Jan Change
19.58 CNY +0.67% Intraday chart for Shijiazhuang Yiling Pharmaceutical Co., Ltd. +1.40% -15.13%
04-26 Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-26 Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * 12.92B 1.78B 143B Sales 2025 * 14.83B 2.05B 164B Capitalization 32.71B 4.51B 362B
Net income 2024 * 2.41B 333M 26.65B Net income 2025 * 2.78B 384M 30.71B EV / Sales 2024 * 2.35 x
Net cash position 2024 * 2.35B 324M 25.93B Net cash position 2025 * 3.46B 477M 38.19B EV / Sales 2025 * 1.97 x
P/E ratio 2024 *
13.6 x
P/E ratio 2025 *
11.8 x
Employees 15,074
Yield 2024 *
2.55%
Yield 2025 *
2.79%
Free-Float 41.69%
More Fundamentals * Assessed data

Chart Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Yiling Pharmaceutical Gets Nod for China Clinical Trial of Tracheobronchitis Drug MT
Yiling Pharmaceutical's Lianhua Qingke Tablets Gets Nod to Become Over-the-Counter Drug; Shares Up 4% MT
Yiling Pharmaceutical Gets Nod to Trial Huoxia Cold Granules MT
Yiling Pharmaceutical Presents Clinical Data on Cardiovascular Drug at Beijing Conference MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Yiling Pharmaceutical Gets Green Light to Trial Acute Myeloid Leukemia Drug MT
Yiling Pharmaceutical Gets Greenlight to Trial G201-Na Capsules MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Announces Implementation of Cash Dividend for 2022, Payable on 17 July 2023 CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022 CI
Yiling Pharma's Hypertension Drug Passes Regulatory Evaluation in China MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022 CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news

Press releases Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Shijiazhuang Yiling Pharmaceutical : Yiling Pharma expects to double its YoY net profit in 2020 AQ
Shijiazhuang Yiling Pharmaceutical : Lianhua Qingwen Listed in the Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme for Laos AQ
More press releases

News in other languages on Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Les "top picks" des gestionnaires de fonds pour 2023
MÄRKTE ASIEN/Ende der Reisebeschränkungen in China stützt Aktien
MORNING BRIEFING - USA/Asien
MÄRKTE ASIEN/Aufhebung von Reisebeschränkungen in China stützt Aktien
MÄRKTE ASIEN/Etwas Fester - US-Zinsentscheid im Fokus
More news

Quotes and Performance

1 day+0.67%
1 week+1.40%
Current month-2.93%
1 month-3.12%
3 months-12.20%
6 months-12.16%
Current year-15.13%
More quotes

Highs and lows

1 week
18.95
Extreme 18.95
19.60
1 month
18.95
Extreme 18.95
20.53
Current year
17.80
Extreme 17.8
24.47
1 year
17.80
Extreme 17.8
33.29
3 years
15.38
Extreme 15.38
53.96
5 years
7.15
Extreme 7.15
53.96
10 years
7.08
Extreme 7.0786
53.96
More quotes

Managers and Directors - Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Xiang Jun Wu CEO
 Chief Executive Officer 49 31/12/04
Chen Guang Li DFI
 Director of Finance/CFO 51 31/12/96
Qiu Lian Zhang BRD
 Director/Board Member 54 15/03/15
Members of the board TitleAgeSince
Yi Ling Wu FOU
 Founder 75 27/08/01
Xiang Jun Wu CEO
 Chief Executive Officer 49 31/12/04
Xue Dong Gao CHM
 Chairman 54 30/08/10
More insiders

ETFs positioned on Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD ETF KraneShares MSCI All China Health Care Index UCITS ETF - USD
0.90% 2 M€ -16.59% -
KRANESHARES CICC CHINA LEADERS 100 INDEX ETF - USD ETF KraneShares CICC China Leaders 100 Index ETF - USD
0.66% 4 M€ -2.96%
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD ETF KraneShares Emerging Market Healthcare Index ETF - Distributing - USD
0.57% 2 M€ -14.14%
More ETFs positioned on Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Quotes

Date Price Change Volume
26/04/24 19.58 +0.67% 15,934,790
25/04/24 19.45 +0.88% 11,485,320
24/04/24 19.28 -0.46% 7,092,839
23/04/24 19.37 +0.52% 11,331,790
22/04/24 19.27 -0.21% 10,261,370

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes

Company Profile

SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company mainly provides cardiovascular and cerebrovascular drugs and anti-cold drugs. The Company also provides food and beverage products. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
26/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
19.58 CNY
Average target price
24.16 CNY
Spread / Average Target
+23.39%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

1st Jan change Capi.
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. Stock Shijiazhuang Yiling Pharmaceutical Co., Ltd.
-15.13% 4.51B
DONG-E-E-JIAO CO.,LTD. Stock Dong-E-E-Jiao Co.,Ltd.
+35.04% 5.92B
TASLY PHARMACEUTICAL GROUP CO., LTD Stock Tasly Pharmaceutical Group Co., Ltd
-9.75% 3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Stock Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
+2.14% 3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. Stock Shandong Buchang Pharmaceuticals Co., Ltd.
-6.82% 2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD. Stock Henan Lingrui Pharmaceutical Co., Ltd.
+47.87% 1.97B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. Stock GuangYuYuan Chinese Herbal Medicine Co., Ltd.
-7.89% 1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD. Stock Tibet Cheezheng Tibetan Medicine Co., Ltd.
+0.09% 1.65B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD Stock Tianjin Chase Sun Pharmaceutical Co.,Ltd
-12.97% 1.53B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD Stock Zhejiang Jolly Pharmaceutical Co.,LTD
+33.40% 1.38B
Alternative Medicine
  1. Stock Market
  2. Equities
  3. 002603 Stock